CoChat

Cardioselective β-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis

Salpeter, Shelley R., Ormiston, Thomas M., Salpeter, Edwin E. · 2002 · Annals of Internal Medicine
Cited by 266

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess the effect of cardioselective beta-blockers on respiratory function of patients with reactive airway disease. DATA SOURCES: Comprehensive searches of the EMBASE, MEDLINE, and CINAHL databases from 1966 to May 2001 and scanning of references of the identified articles and related reviews. STUDY SELECTION: Randomized, blinded, placebo-controlled trials that studied the effects of cardioselective beta-blockers on FEV1, symptoms, and the use of inhaled beta2-agonists in patients with reactive airway disease were selected. Interventions studied were the administration of a cardioselective beta-blocker and administration of beta2-agonist after the study drug. DATA EXTRACTION: Outcomes measured were the change in FEV1 from baseline, the number of patients with respiratory symptoms, and the use of inhaled beta2-agonists with active treatment compared with placebo. DATA SYNTHESIS: Nineteen studies on single-dose treatment and 10 studies on continued treatment were included. Administration of a single dose of a cardioselective beta-blocker was associated with a 7.46% (95% CI, 5.59% to 9.32%) decrease in FEV(1) and a 4.63% (CI, 2.47% to 6.78%) increase in FEV1 response to beta-agonist compared with placebo, with no increase in symptoms. Trials lasting from 3 days to 4 weeks produced no significant change in FEV1 (-0.42% [CI, -3.74% to 2.91%]), symptoms, or inhaler use compared with placebo but maintained an 8.74% (CI, 1.96% to 15.52%) increase in beta-agonist response. No significant treatment effect in terms of FEV1 was found in patients with concomitant chronic obstructive pulmonary disease, whether single doses (change in FEV1, -5.28% [CI, -10.03% to -0.54%]) or continued treatment (change in FEV1, 1.07% [CI, -3.3% to 5.44%]) was given. CONCLUSIONS: Cardioselective beta-blockers do not produce clinically significant adverse respiratory effects in patients with mild to moderate reactive airway disease. The results were similar for patients with concomitant chronic airways obstruction. Given their demonstrated benefit in such conditions as heart failure, cardiac arrhythmias, and hypertension, cardioselective beta-blockers should not be withheld from patients with mild to moderate reactive airway disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-137-9-200211050-00035

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 266

Metadata

Authors
Salpeter, S. R., Ormiston, T. M., & Salpeter, E. E.
Venue
Annals of Internal Medicine
Published
2002-11-05
Volume
137
Issue
9
Pages
715-725
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2172025952
Cited by
266
References
43
FWCI
11.02
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardioselective β-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-137-9-200211050-00035
The paper
Salpeter, S. R., Ormiston, T. M., & Salpeter, E. E. (2002). Cardioselective β-Blockers in Patients with Reactive Airway Disease: A Meta-Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-137-9-200211050-00035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.